Mansi Kanhere1, Jiabei He2, Benoit Chassaing3,4, Thomas R Ziegler5,6, Jessica A Alvarez5, Elizabeth A Ivie5, Li Hao5, John Hanfelt2, Andrew T Gewirtz3, Vin Tangpricha5,6. 1. Division of Endocrinology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia. 2. Rollins School of Public Health, Emory University, Atlanta, Georgia. 3. Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia. 4. Neuroscience Institute, Georgia State University, Atlanta, Georgia. 5. Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. 6. Atlanta VA Medical Center, Decatur, Georgia.
Abstract
Context: Disruption of gut microbiota may exacerbate severity of cystic fibrosis (CF). Vitamin D deficiency is a common comorbidity in patients with CF that may influence composition of the gut microbiota. Objectives: Compare microbiota of vitamin D-sufficient and -insufficient CF patients and assess impact of a weekly high-dose vitamin D3 bolus regimen on gut and airway microbiome in adults with CF and vitamin D insufficiency (25-hydroxyvitamin D < 30 ng/mL). Design: Forty-one subjects with CF were classified into two groups: vitamin D insufficient (n = 23) andvitamin D sufficient (n = 18). Subjects with vitamin D insufficiency were randomized to receive 50,000 IU of oral vitamin D3 or placebo weekly for 12 weeks. Sputum and stool samples were obtained pre- and postintervention and 16S ribosomal RNA genes sequenced using Illumina MiSeq technology. Results: Gut microbiota differed significantly based on vitamin D status with Gammaproteobacteria, which contain numerous, potentially pathogenic species enriched in the vitamin D-insufficient group. Principal coordinates analysis showed differential gut microbiota composition within the vitamin D-insufficient patients following 12 weeks treatment with placebo or vitamin D3 (permutation multivariate analysis of variance = 0.024), with Lactococcus significantly enriched in subjects treated with vitamin D3, whereas Veillonella and Erysipelotrichaceae were significantly enriched in patients treated with placebo. Conclusion: This exploratory study suggests that vitamin D insufficiency is associated with alterations in microbiota composition that may promote inflammation and that supplementation with vitamin D has the potential to impact microbiota composition. Additional studies to determine the impact of vitamin D on microbiota benefit clinical outcomes in CF are warranted.
RCT Entities:
Context: Disruption of gut microbiota may exacerbate severity of cystic fibrosis (CF). Vitamin D deficiency is a common comorbidity in patients with CF that may influence composition of the gut microbiota. Objectives: Compare microbiota of vitamin D-sufficient and -insufficient CFpatients and assess impact of a weekly high-dose vitamin D3 bolus regimen on gut and airway microbiome in adults with CF and vitamin Dinsufficiency (25-hydroxyvitamin D < 30 ng/mL). Design: Forty-one subjects with CF were classified into two groups: vitamin D insufficient (n = 23) and vitamin D sufficient (n = 18). Subjects with vitamin Dinsufficiency were randomized to receive 50,000 IU of oral vitamin D3 or placebo weekly for 12 weeks. Sputum and stool samples were obtained pre- and postintervention and 16S ribosomal RNA genes sequenced using Illumina MiSeq technology. Results: Gut microbiota differed significantly based on vitamin D status with Gammaproteobacteria, which contain numerous, potentially pathogenic species enriched in the vitamin D-insufficient group. Principal coordinates analysis showed differential gut microbiota composition within the vitamin D-insufficient patients following 12 weeks treatment with placebo or vitamin D3 (permutation multivariate analysis of variance = 0.024), with Lactococcus significantly enriched in subjects treated with vitamin D3, whereas Veillonella and Erysipelotrichaceae were significantly enriched in patients treated with placebo. Conclusion: This exploratory study suggests that vitamin Dinsufficiency is associated with alterations in microbiota composition that may promote inflammation and that supplementation with vitamin D has the potential to impact microbiota composition. Additional studies to determine the impact of vitamin D on microbiota benefit clinical outcomes in CF are warranted.
Authors: Yunzi Chen; Weicheng Liu; Tao Sun; Yong Huang; Youli Wang; Dilip K Deb; Dosuk Yoon; Juan Kong; Ravi Thadhani; Yan Chun Li Journal: J Immunol Date: 2013-02-22 Impact factor: 5.422
Authors: V Tangpricha; A Kelly; A Stephenson; K Maguiness; J Enders; K A Robinson; B C Marshall; D Borowitz Journal: J Clin Endocrinol Metab Date: 2012-03-07 Impact factor: 5.958
Authors: Duy M Dinh; Gretchen E Volpe; Chad Duffalo; Seema Bhalchandra; Albert K Tai; Anne V Kane; Christine A Wanke; Honorine D Ward Journal: J Infect Dis Date: 2014-07-23 Impact factor: 5.226
Authors: Jack A Gilbert; Folker Meyer; Janet Jansson; Jeff Gordon; Norman Pace; James Tiedje; Ruth Ley; Noah Fierer; Dawn Field; Nikos Kyrpides; Frank-Oliver Glöckner; Hans-Peter Klenk; K Eric Wommack; Elizabeth Glass; Kathryn Docherty; Rachel Gallery; Rick Stevens; Rob Knight Journal: Stand Genomic Sci Date: 2010-12-25
Authors: Bryan Coburn; Pauline W Wang; Julio Diaz Caballero; Shawn T Clark; Vijaya Brahma; Sylva Donaldson; Yu Zhang; Anu Surendra; Yunchen Gong; D Elizabeth Tullis; Yvonne C W Yau; Valerie J Waters; David M Hwang; David S Guttman Journal: Sci Rep Date: 2015-05-14 Impact factor: 4.379
Authors: John Michael S Sanchez; Ana Beatriz DePaula-Silva; Jane E Libbey; Robert S Fujinami Journal: Clin Immunol Date: 2020-03-07 Impact factor: 3.969
Authors: Anirudh Bhimavarapu; Qiao Deng; Marta Bean; Nick Lee; Thomas R Ziegler; Jessica Alvarez; Vin Tangpricha Journal: Am J Med Sci Date: 2020-08-20 Impact factor: 2.378
Authors: Albert Shieh; S Melanie Lee; Venu Lagishetty; Carter Gottleib; Jonathan P Jacobs; John S Adams Journal: J Clin Endocrinol Metab Date: 2021-11-19 Impact factor: 6.134